TEVA PHARMACEUTICAL INDUSTRIES LTD

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

TEVA$42.61+2.0%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated statements of changes in equity

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive income (loss)	Treasury shares	Total Teva shareholders’ equity	Non- controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2024	1,240	58	27,764	(15,173)	(3,148)	(4,128)	5,373	7	5,380
Net Income (loss)				214			214	*	214
Other comprehensive income (loss)					473		473	*	473
Issuance of Shares	13	*					*		*
Proceeds from exercise of options			3				3		3
Stock-based compensation expense			34				34		34
Purchase of shares from redeemable non-controlling interests**			165				165		165
Balance at March 31, 2025	1,253	$58	$27,965	$(14,958)	$(2,675)	$(4,128)	$6,262	$7	$6,269

*	Represents an amount less than $0.5 million.

**	In connection with the sale of Teva’s business venture in Japan. See note 17.

	Teva shareholders’ equity
	Ordinary shares
	Number of shares (in millions)	Stated value	Additional paid-in capital	Retained earnings (accumulated deficit)	Accumulated other comprehensive income (loss)	Treasury shares	Total Teva shareholders’ equity	Non- controlling interests	Total equity
(U.S. dollars in millions)
Balance at December 31, 2023	1,227	57	27,807	(13,534)	(2,697)	(4,128)	7,506	620	8,126
Net Income (loss)				(139)			(139)	(280)	(419)
Other comprehensive income (loss)					(75)		(75)	(42)	(117)
Issuance of shares	11	1	*				1		1
Stock-based compensation expense			28				28		28
Proceeds from exercise of options			6				6		6
Dividend to non-controlling interests**								(18)	(18)
Purchase of shares from non-controlling interests***			(45)		(3)		(48)	(16)	(64)
Balance at March 31, 2024	1,238	$58	$27,796	$(13,673)	$(2,775)	$(4,128)	$7,279	$265	$7,543

*	Represents an amount less than $0.5 million.

**	In connection with the dividend to non-controlling interest in Teva’s business venture in Japan.

***	Purchase of shares from non-controlling interests in Teva’s subsidiary in Switzerland.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.